Karyopharm Therapeutics (FRA:25K) Marketable Securities : €108.5 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Karyopharm Therapeutics's Marketable Securities for the quarter that ended in Mar. 2024 was €108.5 Mil.

Karyopharm Therapeutics's annual Marketable Securities increased from Dec. 2021 (€33.8 Mil) to Dec. 2022 (€134.8 Mil) but then declined from Dec. 2022 (€134.8 Mil) to Dec. 2023 (€127.7 Mil).

Karyopharm Therapeutics Marketable Securities Historical Data

The historical data trend for Karyopharm Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Marketable Securities Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

119.79

134.25

33.77

134.78

127.66

Karyopharm Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															164.69	143.87	154.29	127.66	108.51

Karyopharm Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Karyopharm Therapeutics (FRA:25K) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Karyopharm Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics (FRA:25K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

KPTI:USA

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines